Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04274426
Title Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors AGO Research GmbH
Indications

ovary epithelial cancer

ovarian carcinosarcoma

fallopian tube cancer

peritoneum cancer

ovarian carcinoma

Therapies

Carboplatin + Paclitaxel

Carboplatin + Gemcitabine

Carboplatin + Pegylated liposomal-doxorubicin

Carboplatin + Mirvetuximab Soravtansine

Age Groups: adult | senior
Covered Countries


No variant requirements are available.